Cargando…

Nonalcoholic Steatohepatitis: A 9-Year Follow Up Cohort Study

Background and aim: Non-alcoholic fatty liver disease (NAFLD) may progress to severe liver fibrosis and cirrhosis. A limited number of studies with a long follow up assessed fibrosis progression and related predictors in untreated patients with a histological diagnosis of NAFLD. This study aims to i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mangia, Alessandra, Piazzolla, Annarita Valeria, Squillante, Maria Maddalena, Cocomazzi, Giovanna, Valori, Vanna Maria, Copetti, Massimiliano, Parente, Paola, Attino, Vito, Guido, Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9573625/ https://www.ncbi.nlm.nih.gov/pubmed/36233834 http://dx.doi.org/10.3390/jcm11195969

Ejemplares similares

Hepatitis C virus micro-elimination: Where do we stand?
por: Mangia, Alessandra, et al.
Publicado: (2021)

Durability of immune response to SARS-CoV-2 vaccination in patients with liver cirrhosis (LC) as compared to healthcare workers (HW)
por: Mangia, Alessandra, et al.
Publicado: (2022)

Effectiveness of Booster Dose of Anti SARS-CoV-2 BNT162b2 in Cirrhosis: Longitudinal Evaluation of Humoral and Cellular Response
por: Giambra, Vincenzo, et al.
Publicado: (2022)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
por: Cocomazzi, Giovanna, et al.
Publicado: (2021)

Is positivity for hepatitis C virus antibody predictive of lower risk of death in COVID-19 patients with cirrhosis?
por: Mangia, Alessandra, et al.
Publicado: (2020)

HDV RNA Levels and Progression of Hepatitis Delta Infection: A 14 Year Follow Up Experience in Italy
por: Mangia, Alessandra, et al.
Publicado: (2023)

SVR12 Higher than 97% in GT3 Cirrhotic Patients with Evidence of Portal Hypertension Treated with SOF/VEL without Ribavirin: A Nation-Wide Cohort Study
por: Mangia, Alessandra, et al.
Publicado: (2019)

Increased Hepatitis C virus screening, diagnosis and linkage to care rates among people who use drugs through a patient‐centered program from Italy
por: Mangia, Alessandra, et al.
Publicado: (2021)

Noninvasive Diagnosis of NAFLD and NASH
por: Piazzolla, Valeria Annarita, et al.
Publicado: (2020)

437 A TAILORED PROGRAM FOR SCREENING, IMPROVED ACCESS TO CARE, AND PRIORITIZATION OF TREATMENT FOR PWUD WITH CHRONIC HCV INFECTION.
por: Mangia, Alessandra, et al.
Publicado: (2021)

Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
por: Savino, Maria, et al.
Publicado: (2009)

Cellular and Humoral Immune Responses and Breakthrough Infections After Two Doses of BNT162b Vaccine in Healthcare Workers (HW) 180 Days After the Second Vaccine Dose
por: Mangia, Alessandra, et al.
Publicado: (2022)

Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients
por: Barbano, Raffaela, et al.
Publicado: (2015)

High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55–85
por: Piazzolla, Annarita Valeria, et al.
Publicado: (2021)

Hepatocellular carcinoma in adult thalassemia patients: an expert opinion based on current evidence
por: Mangia, Alessandra, et al.
Publicado: (2020)

Human Nonalcoholic Steatohepatitis on a Chip
por: Freag, May S., et al.
Publicado: (2020)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Targeting MRG15 for the treatment of nonalcoholic steatohepatitis
por: Zhang, Yao, et al.
Publicado: (2022)

Stepwise analysis of MIR9 loci identifies miR-9-5p to be involved in Oestrogen regulated pathways in breast cancer patients
por: Barbano, Raffaela, et al.
Publicado: (2017)

Cytokines Genotype-Phenotype Correlation in Nonalcoholic Steatohepatitis
por: Bocsan, Ioana Corina, et al.
Publicado: (2017)

Hsa-miR-210-3p expression in breast cancer and its putative association with worse outcome in patients treated with Docetaxel
por: Pasculli, Barbara, et al.
Publicado: (2019)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis
por: Dongiovanni, Paola, et al.
Publicado: (2015)

Overexpression of the Vitronectin V10 Subunit in Patients with Nonalcoholic Steatohepatitis: Implications for Noninvasive Diagnosis of NASH
por: Del Ben, Maria, et al.
Publicado: (2018)

Rodent Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
por: Imajo, Kento, et al.
Publicado: (2013)

Wilson's disease masquerading as nonalcoholic steatohepatitis
por: Mahmood, Sabina, et al.
Publicado: (2009)

Familial Hypobetalipoproteinemia-Induced Nonalcoholic Steatohepatitis
por: Lam, Mindy C.W., et al.
Publicado: (2012)

The effect of β-caryophyllene on nonalcoholic steatohepatitis
por: Arizuka, Naoya, et al.
Publicado: (2017)

New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis
por: Mendez-Sanchez, Nahum, et al.
Publicado: (2018)

Repurposing drugs to target nonalcoholic steatohepatitis
por: Sookoian, Silvia, et al.
Publicado: (2019)

The regulatory state of nonalcoholic steatohepatitis and metabolism
por: Omokaro, Stephanie O., et al.
Publicado: (2020)

Antidiabetic Therapy in the Treatment of Nonalcoholic Steatohepatitis
por: Sumida, Yoshio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qduk6sebi95t1uihs2j3e07imt